Loading...
•
Apr 03, 2021
Haemonetics Q4 2021 Earnings Report
Haemonetics' Q4 2021 financial results were reported, showing a decrease in revenue compared to the previous year, impacted by the COVID-19 pandemic but partially offset by cost mitigation efforts and the Operational Excellence Program.
Key Takeaways
Haemonetics reported a decrease in Q4 revenue by 5.6% to $225 million, primarily driven by the continued impact of COVID-19. The company experienced an operating loss of $21.2 million, and a net loss of $11.0 million, or $0.22 per share. Adjusted earnings per diluted share were $0.46. The company issued its FY2022 revenue growth guidance of 13–18%.
Q4 revenue decreased by 5.6% to $225 million due to the continued impact of COVID-19.
Operating loss was $21.2 million, compared to an operating income of $26.0 million in the prior year.
Net loss was $11.0 million, or $0.22 per share, compared to a net income of $17.6 million, or $0.34 per share in the prior year.
Adjusted earnings per diluted share were $0.46, down 33.3% compared to the prior year.
Revenue by Segment
Forward Guidance
The Company issued its GAAP total revenue growth guidance of 13 – 18% and organic revenue growth guidance as follows: Organic1Total revenue8 - 12%Plasma revenue15 - 25%Hospital Revenue15 - 20%Blood Center revenue(6 - 8%)
Positive Outlook
- Total company GAAP revenue guidance includes $65 - $75 million revenue related to our Cardiva Medical Vascular Closure devices.
- Hospital organic revenue guidance includes a Hemostasis Management organic revenue growth in the mid-twenties.
- Adjusted operating margin19 - 20%
- Adjusted earnings per diluted share$2.60 - $3.00
- Free cash flow, before restructuring & turnaround$135M - $155M
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...